Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).

Veröffentlicht vonadmin

Fridrik, MA, Jaeger, U, Petzer, A, Willenbacher, W, Keil, F, Lang, A, Andel, J, Burgstaller, S, Krieger, O, Oberaigner, W, Sihorsch, K, Greil, R.

http://www.ncbi.nlm.nih.gov/pubmed/26990931